Brainstorm Cell Therapeutics, Inc. (BCLI)
0.8219
+0.05
(+5.91%)
USD |
OTCM |
Oct 23, 16:00
Brainstorm Cell Therapeutics Enterprise Value : 10.42M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 10.42M |
| October 22, 2026 | 9.915M |
| October 21, 2026 | 9.849M |
| October 20, 2026 | 10.18M |
| October 19, 2026 | 9.849M |
| October 16, 2026 | 9.949M |
| October 15, 2026 | 10.18M |
| October 14, 2026 | 10.57M |
| October 13, 2026 | 10.53M |
| October 12, 2026 | 10.75M |
| October 09, 2026 | 11.83M |
| October 08, 2026 | 11.43M |
| October 07, 2026 | 11.28M |
| October 06, 2026 | 12.72M |
| October 05, 2026 | 12.94M |
| October 02, 2026 | 11.62M |
| October 01, 2026 | 12.39M |
| September 30, 2026 | 11.84M |
| September 29, 2026 | 11.50M |
| September 28, 2026 | 11.68M |
| September 25, 2026 | 12.06M |
| September 24, 2026 | 11.83M |
| September 23, 2026 | 10.95M |
| September 22, 2026 | 11.76M |
| September 21, 2026 | 10.95M |
| Date | Value |
|---|---|
| September 18, 2026 | 11.28M |
| September 17, 2026 | 12.17M |
| September 16, 2026 | 12.16M |
| September 15, 2026 | 12.83M |
| September 14, 2026 | 13.08M |
| September 11, 2026 | 13.27M |
| September 10, 2026 | 12.72M |
| September 09, 2026 | 12.39M |
| September 08, 2026 | 12.28M |
| September 04, 2026 | 12.94M |
| September 03, 2026 | 13.16M |
| September 02, 2026 | 15.15M |
| September 01, 2026 | 14.24M |
| August 31, 2026 | 13.10M |
| August 28, 2026 | 13.75M |
| August 27, 2026 | 14.18M |
| August 26, 2026 | 14.59M |
| August 25, 2026 | 12.39M |
| August 24, 2026 | 12.39M |
| August 21, 2026 | 12.17M |
| August 20, 2026 | 13.05M |
| August 19, 2026 | 14.79M |
| August 18, 2026 | 16.91M |
| August 17, 2026 | 13.33M |
| August 14, 2026 | 12.28M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.047M |
| Summit Therapeutics, Inc. | 11.60B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | -2.080M |
| Clene, Inc. | 62.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.855M |
| Total Expenses (Quarterly) | 3.855M |
| EPS Diluted (Quarterly) | -0.3494 |
| Earnings Yield | -116.1% |
| Normalized Earnings Yield | -116.07 |